dotinurad

Dotinurad is a novel, orally available small molecule drug indicated for the treatment of hyperuricemia, including gout. It acts as a selective urate reabsorption inhibitor (SURI) by selectively inhibiting urate transporter 1 (URAT1), which is expressed on the proximal renal tubules and responsible for reabsorption of uric acid. By blocking URAT1, dotinurad reduces serum uric acid levels by promoting urinary excretion of uric acid while having minimal effects on other transporters involved in uric acid secretion. Dotinurad was discovered and developed by Fuji Yakuhin and has been approved in Japan since 2020 and in China since 2024 for the treatment of hyperuricemia with or without gout[3][5][6][7]. Clinical trials have demonstrated its efficacy in lowering serum uric acid levels with a favorable safety profile[4][8].

Brand names

Urece优乐思

Other names

多替诺雷片